Literature DB >> 15965501

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Güllü Görgün1, Tobias A W Holderried, David Zahrieh, Donna Neuberg, John G Gribben.   

Abstract

To examine the impact of tumors on the immune system, we compared global gene expression profiles of peripheral blood T cells from previously untreated patients with B cell chronic lymphocytic leukemia (CLL) with those from age-matched healthy donors. Although the cells analyzed were not part of the malignant clone, analysis revealed differentially expressed genes, mainly involved in cell differentiation in CD4 cells and defects in cytoskeleton formation, vesicle trafficking, and cytotoxicity in CD8 cells of the CLL patients. In coculture experiments using CLL cells and T cells from healthy allogeneic donors, similar defects developed in both CD4 and CD8 cells. These changes were induced only with direct contact and were not cytokine mediated. Identification of the specific pathways perturbed in the T cells of cancer-bearing patients will allow us to assess steps to repair these defects, which will likely be required to enhance antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965501      PMCID: PMC1150284          DOI: 10.1172/JCI24176

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Molecular cloning of MINK, a novel member of mammalian GCK family kinases, which is up-regulated during postnatal mouse cerebral development.

Authors:  I Dan; N M Watanabe; T Kobayashi; K Yamashita-Suzuki; Y Fukagaya; E Kajikawa; W K Kimura; T M Nakashima; K Matsumoto; J Ninomiya-Tsuji; A Kusumi
Journal:  FEBS Lett       Date:  2000-03-03       Impact factor: 4.124

2.  Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI.

Authors:  G R Hoffman; N Nassar; R A Cerione
Journal:  Cell       Date:  2000-02-04       Impact factor: 41.582

3.  The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI.

Authors:  K Scheffzek; I Stephan; O N Jensen; D Illenberger; P Gierschik
Journal:  Nat Struct Biol       Date:  2000-02

4.  FRL, a novel formin-related protein, binds to Rac and regulates cell motility and survival of macrophages.

Authors:  S Yayoshi-Yamamoto; I Taniuchi; T Watanabe
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

Authors:  L Fayad; M J Keating; J M Reuben; S O'Brien; B N Lee; S Lerner; R Kurzrock
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.

Authors:  N E Kay; L Han; N Bone; G Williams
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

7.  Interactions of ADF/cofilin, Arp2/3 complex, capping protein and profilin in remodeling of branched actin filament networks.

Authors:  L Blanchoin; T D Pollard; R D Mullins
Journal:  Curr Biol       Date:  2000-10-19       Impact factor: 10.834

8.  The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity.

Authors:  S M Waugh; J L Harris; R Fletterick; C S Craik
Journal:  Nat Struct Biol       Date:  2000-09

9.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

10.  c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation.

Authors:  K Sabapathy; T Kallunki; J P David; I Graef; M Karin; E F Wagner
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  114 in total

Review 1.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

2.  CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Authors:  Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

3.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Authors:  Xueqing Liang; E Ashley Moseman; Michael A Farrar; Veronika Bachanova; Daniel J Weisdorf; Bruce R Blazar; Wei Chen
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

4.  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Authors:  Mark B Geyer; Isabelle Rivière; Brigitte Sénéchal; Xiuyan Wang; Yongzeng Wang; Terence J Purdon; Meier Hsu; Sean M Devlin; M Lia Palomba; Elizabeth Halton; Yvette Bernal; Dayenne G van Leeuwen; Michel Sadelain; Jae H Park; Renier J Brentjens
Journal:  JCI Insight       Date:  2019-04-02

5.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

6.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

7.  FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia.

Authors:  Daniel M Schreeder; Jicun Pan; Fu Jun Li; Eric Vivier; Randall S Davis
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

8.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

9.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

10.  Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Authors:  Robert Weinkove; Collin R Brooks; John M Carter; Ian F Hermans; Franca Ronchese
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.